Clinical trials: Peritoneal Cavity Cancer, open to volunteers
Peritoneal (Metastatic) Cancer, Peritoneal Carcinoma
Paricalcitol Versus Pirfenidone for Improving Surgical Resectability in Patients With Peritoneal Cancer
The goal of this clinical trial is to learn if paricalcitol or pirfenidone can help make tumors removable by surgery in adults with peritoneal cancer who are currently unable to have their tumor removed.
- Conditions
- Peritoneal (Metastatic) Cancer, Peritoneal Carcinoma, Peritoneal Carcinosis, Peritoneal Cancer
- Trial name
- RANDY 1A (NCT07856914)
- Testing
- Paricalcitol, pirfenidone
- Volunteers
- 74 people
- Sponsor
- Patrick Wagner, MD, FACS
Malignant Peritoneal Effusion, Malignant Ascites
Dual-targeting VEGFR1 and PD-L1 CAR-T for Pleural, Peritoneal, or Leptomeningeal Metastases
This is a Phase I, open-label, single-arm, dose-escalation and expansion study designed to evaluate the safety, tolerability, and preliminary antitumor activity of dual-targeting VEGFR1/PD-L1 chimeric antigen receptor (CAR)…
- Conditions
- Malignant Peritoneal Effusion, Malignant Ascites, Serous Cavity Metastatises, Leptomeningeal Metastases
- Trial name
- NCT05477927
- Testing
- Dual-targeting VEGFR1/PD-L1 CAR-T cells
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sichuan University
Pancreatic Cancer, Thyroid Cancer
Integrated Cancer Repository for Cancer Research
The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer…
- Conditions
- Pancreatic Cancer, Thyroid Cancer, Lung Cancer, Esophageal Cancer
- Trial name
- iCaRe2 (NCT02012699)
- Where
- 42 sites in United States
- Volunteers
- 999,999 people, healthy volunteers welcome
- Sponsor
- University of Nebraska
Triple Negative Breast Cancer, Breast Cancer
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
A Study of Emi-Le in Participants with Solid Tumors
- Conditions
- Triple Negative Breast Cancer, Breast Cancer, Endometrial Cancer, Ovarian Cancer
- Trial name
- NCT05377996
- Testing
- Emi-Le
- Where
- 26 sites in United States
- Volunteers
- 360 people
- Sponsor
- Day One Biopharmaceuticals, Inc.